Streetbeat News

Analyst Ratings

AR

Truist Securities analyst Bertrand Hodee maintains a 'Buy' rating on Antero Resources (NYSE:AR) and raises the price target from $32 to $36.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 2:14 pm

CHK

Truist Securities analyst Neal Dingmann has maintained a 'Buy' rating on Chesapeake Energy (NASDAQ:CHK) and raised the price target from $100 to $110.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 2:13 pm

GPOR

Truist Securities analyst Neal Dingmann maintains a Buy rating on Gulfport Energy (NYSE:GPOR) and raises the price target from $134 to $150.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 2:12 pm

SWN

Truist Securities analyst Neal Dingmann has maintained a 'Buy' rating on Southwestern Energy (NYSE:SWN) and raised the price target from $8 to $9.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 2:11 pm

EQT

Truist Securities analyst Neal Dingmann has maintained a 'Hold' rating on EQT (NYSE:EQT) and raised the price target from $35 to $39.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 2:10 pm

RRC

Truist Securities analyst Bertrand Hodee has maintained a 'Hold' rating on Range Resources (NYSE:RRC) and raised the price target from $29 to $32.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 2:10 pm

ORCL

Oracle Corporation (NYSE:ORCL) is expected to report higher Q1 earnings for fiscal year 2024, with analysts predicting a rise from $1.03 to $1.14 per share. The company's revenue is also expected to increase from $11.45 billion to $12.46 billion. Oracle's stock price closed at $126.32 on Friday, up 1%. Several analysts have recently updated their price targets for Oracle, with the highest being $145.

Portfolio Pulse from Lisa Levin

September 11, 2023 | 2:09 pm

CRK

Truist Securities analyst Neal Dingmann maintains a 'Hold' rating on Comstock Resources (NYSE:CRK) and raises the price target from $10 to $12.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 2:07 pm

CRNX

Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) announced that its Phase 3 PATHFNDR-1 study evaluating paltusotine met the primary and secondary endpoints in acromegaly patients. The company plans to submit a new drug application to the FDA in 2024. The company's shares are up 67.40% at $26.74.

Portfolio Pulse from Vandana Singh

September 11, 2023 | 2:05 pm

CNX

Truist Securities analyst Bertrand Hodee has maintained a 'Hold' rating on CNX Resources (NYSE:CNX) and raised the price target from $19 to $21.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 2:05 pm